Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/LPP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LPP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LPP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LPP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LPP_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LPP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/LPP_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LPP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LPP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LPP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/LPP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LPP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LPP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051403110 | Skin | SCCIS | stress-activated MAPK cascade | 31/919 | 239/18723 | 7.71e-07 | 5.68e-05 | 31 |
GO:006007018 | Skin | SCCIS | canonical Wnt signaling pathway | 36/919 | 303/18723 | 8.82e-07 | 6.24e-05 | 36 |
GO:0031098110 | Skin | SCCIS | stress-activated protein kinase signaling cascade | 31/919 | 247/18723 | 1.57e-06 | 9.08e-05 | 31 |
GO:0048511110 | Skin | SCCIS | rhythmic process | 35/919 | 298/18723 | 1.63e-06 | 9.13e-05 | 35 |
GO:003362714 | Skin | SCCIS | cell adhesion mediated by integrin | 15/919 | 72/18723 | 1.73e-06 | 9.54e-05 | 15 |
GO:0001667111 | Skin | SCCIS | ameboidal-type cell migration | 48/919 | 475/18723 | 1.78e-06 | 9.73e-05 | 48 |
GO:006104119 | Skin | SCCIS | regulation of wound healing | 21/919 | 134/18723 | 2.31e-06 | 1.17e-04 | 21 |
GO:003287219 | Skin | SCCIS | regulation of stress-activated MAPK cascade | 26/919 | 192/18723 | 2.64e-06 | 1.28e-04 | 26 |
GO:007030219 | Skin | SCCIS | regulation of stress-activated protein kinase signaling cascade | 26/919 | 195/18723 | 3.53e-06 | 1.62e-04 | 26 |
GO:0022409110 | Skin | SCCIS | positive regulation of cell-cell adhesion | 33/919 | 284/18723 | 4.06e-06 | 1.82e-04 | 33 |
GO:0007623110 | Skin | SCCIS | circadian rhythm | 27/919 | 210/18723 | 4.64e-06 | 1.94e-04 | 27 |
GO:004349115 | Skin | SCCIS | protein kinase B signaling | 27/919 | 211/18723 | 5.07e-06 | 2.09e-04 | 27 |
GO:0034109111 | Skin | SCCIS | homotypic cell-cell adhesion | 16/919 | 90/18723 | 7.01e-06 | 2.70e-04 | 16 |
GO:000725417 | Skin | SCCIS | JNK cascade | 23/919 | 167/18723 | 7.39e-06 | 2.80e-04 | 23 |
GO:004354217 | Skin | SCCIS | endothelial cell migration | 32/919 | 279/18723 | 7.43e-06 | 2.80e-04 | 32 |
GO:1903034110 | Skin | SCCIS | regulation of response to wounding | 22/919 | 167/18723 | 2.36e-05 | 6.65e-04 | 22 |
GO:004632815 | Skin | SCCIS | regulation of JNK cascade | 19/919 | 133/18723 | 2.68e-05 | 7.41e-04 | 19 |
GO:005189615 | Skin | SCCIS | regulation of protein kinase B signaling | 23/919 | 185/18723 | 3.96e-05 | 1.01e-03 | 23 |
GO:0010632110 | Skin | SCCIS | regulation of epithelial cell migration | 31/919 | 292/18723 | 4.68e-05 | 1.16e-03 | 31 |
GO:0045936112 | Skin | SCCIS | negative regulation of phosphate metabolic process | 41/919 | 441/18723 | 6.90e-05 | 1.63e-03 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LPP | SNV | Missense_Mutation | rs749505857 | c.1396G>A | p.Glu466Lys | p.E466K | | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LPP | SNV | Missense_Mutation | | c.922N>C | p.Gly308Arg | p.G308R | | protein_coding | tolerated(0.11) | possibly_damaging(0.818) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
LPP | SNV | Missense_Mutation | rs756003756 | c.1457G>A | p.Arg486Gln | p.R486Q | | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | | c.254N>G | p.Ser85Cys | p.S85C | | protein_coding | tolerated(0.05) | benign(0.276) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
LPP | SNV | Missense_Mutation | | c.1834N>G | p.Leu612Val | p.L612V | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.974) | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | novel | c.1576N>A | p.Glu526Lys | p.E526K | | protein_coding | deleterious(0) | possibly_damaging(0.57) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | novel | c.1274N>T | p.Gly425Val | p.G425V | | protein_coding | deleterious(0) | possibly_damaging(0.874) | TCGA-AC-A2QH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
LPP | SNV | Missense_Mutation | | c.1391N>G | p.Tyr464Cys | p.Y464C | | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
LPP | SNV | Missense_Mutation | novel | c.452N>G | p.Ser151Cys | p.S151C | | protein_coding | deleterious(0.02) | possibly_damaging(0.885) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
LPP | SNV | Missense_Mutation | | c.1751N>A | p.Cys584Tyr | p.C584Y | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |